Journal article

Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3

Srinivas R Sadda, Robyn Guymer, Frank G Holz, Steffen Schmitz-Valckenberg, Christine A Curcio, Alan C Bird, Barbara A Blodi, Ferdinando Bottoni, Usha Chakravarthy, Emily Y Chew, Karl Csaky, Ronald P Danis, Monika Fleckenstein, K Bailey Freund, Juan Grunwald, Carel B Hoyng, Glenn J Jaffe, Sandra Liakopoulos, Jordi M Mones, Daniel Pauleikhoff Show all

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2018

Grants

Awarded by National Institutes of Health, Bethesda, Maryland


Awarded by NATIONAL EYE INSTITUTE


Funding Acknowledgements

The author(s) have made the following disclosure(s): S.R.S.: Consultant - Allergan, Iconic Therapeutics, Novartis, Thrombogenics, Genentech, Centervue, Heidelberg Engineering; Research support - Optos, Carl Zeiss Meditec, Allergan; Research Instruments - Optos, Carl Zeiss Meditec, Nidek, Centervue, Heidelberg EngineeringR.G.: Financial support - Novartis, Bayer, GenentechF.G.H.: Financial support - Heidelberg Engineering, Optos, Zeiss, Novartis, Bayer Healthcare, Genentech, Acucela, Boehringer Ingelheim, Alcon, AllerganS.S.-V.: Financial support - Novartis, Bayer Healthcare, Genentech, Acucela, Alcon, Allergan, Heidelberg Engineering, Formycon/Bioeq; Nonfinancial support - Optos, Heidelberg Engineering, Carl Zeiss MeditecC.A.C.: Financial support - Hoffman-LaRoche, Heidelberg Engineering, Regeneron, Novartis, Unity, Janssen Cell TherapyK.C.: Financial support - Genentech, Regeneron, Heidelberg Engineering, Santen, Ophthotech, Acucela, GSK, Roche, Allergan; Other - OphthotechR.D.: Financial support - Allergan, GSK, Thrombogenics, KangHong, Ionis; Equity owner - EyeKor, Inc; Employee - EyeKor, IncK.B.F.: Consultant - Heidelberg Engineering, Optovue, Optos, Spark Therapeutics; Financial support - Genentech/RocheJ.M.M.: Financial support - Eyerisk Consortium 2020, Novartis, Bayer, Alcon, Roche, Ophthotech; Consultant - Novartis, Bayer, Alcon, Roche, Genentech; Equity owner - Ophthotech, NotalvisionP.J.R.: Research support - Astellas Institute for Regenerative Medicine (AIRM), Carl Zeiss Meditec, Genentech, Tyrogenex; Consultant - Acucela, Apellis, Boehringer-Ingelheim, Carl Zeiss Meditec, Cell Cure Neurosciences, Chengdu Kanghong Biotech, Isarna Therapeutics, Genentech, Healios K.K., Hemera Biosciences, F. Hoffmann-La Roche Ltd., Ocudyne, Ocunexus, Tyrogenex, Unity Biotechnology; Equity Interest - Apellis, Digisight, OcudyneD.S.: Consultant - Genentech, Optovue, Bayer, Novartis; Financial support - Allergan, Genentech, Heidelberg Engineering, Regeneron, Optovue, Optovue; Lecturer - OptovueR.T.: Financial support - Alcon, Allergan, Alimera, Novartis, Bayer, B+L, FCI, Zeiss, Thromgenics, Genentech, Roche; Nonfinancial support - Alcon, Allergan, Novartis, Bayer, B+L, ZeissG.S.: Financial support - Heidelberg Engineering, Zeiss Meditec, Optovue, Optos, Centervue, Nidek, Novartis, Bayer; Other - Heidelberg Engineering, Zeiss Meditec, Optos, Centervue, Novartis, Bayer, Boeheringer, Allergan, AlconAcquisition of human donor eyes and the Project MACULA web site were supported by the National Institutes of Health, Bethesda, Maryland (grant nos.: R01EY06019 and P30 EY003039 [C.A.C.]); EyeSight Foundation of Alabama (C.A.C.); International Retinal Research Foundation (C.A.C.); the Edward N. and Della L. Thome Foundation (C.A.C.); the Arnold and Mabel Beckman Initiative for Macular Research (C.A.C.); and Research to Prevent Blindness, Inc, New York, New York (C.A.C.). Supported by the Lowy Research Medical Institute (travel grant, A.C.B.).